CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS TESTANT LE ROLE DE LA DOSE DE CISPLATINE


Précédent Retour au menu principal  Suivant


référence

Schéma de chimiothérapie

n

(st IV)

% R0

p

SM

p

Gralla,

1981

I. CDDP (120 mg/m2) +VDS

41

 

40

NS

 

NS

II. CDDP (60 mg/m2) +VDS

40

 

46

 

Klastersky,

1986

CDDP-VP16

     

 

NS

 

 

NS

I. 120 mg/m2

116

(63)

29

28 s

II. 60 mg/m2

125

(76)

25

33 s

Shinkai,

1986

I. CDDP (120 mg/m2) +VDS

24

(19)

39

NS

9 m

 

II. CDDP (80 mg/m2) +VDS

21

(16)

33

10,8 m

Gandara

1993

CDDP

     

 

NS

 

 

NS

I. 2 x 100 mg/m2

108

(108)

14

5,3 m

II. 2 x 50 mg/m2

105

(105)

12

6,9 m

Sculier,

2000

Ifo – MMC

     

 

NS

 

 

NS

I.CDDP 50 mg/m²

147

(143)

27%

28 s

II. CDDP 60 mg/m² + CBDCA (200 mg/m²)

150

(145)

33%

32 s




Références

(1) Gralla RJ, Casper ES, Kelsen DP, Braun DWJ, Dukeman ME, Martini N et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95(4):414-420.

(2) Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986; 4(12):1780-1786.

(3) Shinkai T, Saijo N, Eguchi K, Sasaki Y, Tominaga K, Sakurai M et al. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 1986; 77(8):782-789.

(4) Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11(5):873-878.

(5) Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumohl J et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000; 83(9):1128-1135.



Retour au début de la page